Inactive Instrument

Aastrom Biosciences Inc Stock price Nasdaq

Equities

US00253U3059

Pharmaceuticals

End-of-day quote Nasdaq
- USD 0.00% Intraday chart for Aastrom Biosciences Inc
Sales 2024 * 239M Sales 2025 * 299M Capitalization 2.53B
Net income 2024 * 4M Net income 2025 * 25M EV / Sales 2024 * 10.6 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 8.45 x
P/E ratio 2024 *
654 x
P/E ratio 2025 *
108 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.17%
More Fundamentals * Assessed data

Latest transcript on Aastrom Biosciences Inc

Managers TitleAgeSince
Chief Executive Officer 60 13-02-28
Director of Finance/CFO 49 21-01-24
Chief Operating Officer 62 17-04-09
Members of the board TitleAgeSince
Director/Board Member 63 15-01-05
Director/Board Member 67 15-01-05
Chairman 73 06-01-15
More insiders
Vericel Corporation is engaged in advanced therapies for the sports medicine and severe burn care markets. The Company markets two cell therapy products and one specialty biologic product in the United States. MACI (autologous cultured chondrocytes onporcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single ormultiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Calendar
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Vericel Corporation
  4. Stock Aastrom Biosciences Inc - Nasdaq